

**Conference Call Q3 2016 Financial Results** 

27 October 2016



# Summary of Q3 2016 Financial Results

Healthy bottom line supported by core earnings and non-recurring gains



Unit: MMUSD

Statement of Income	Q2 16 *	Q3 16	% QoQ	Q3 15 *	% YoY	9M 16	9M 15 *	% YTD
Total Revenues	1,102	1,109	1	1,457	(24)	3,281	4,291	(24)
Sales	1,061	1,047	(1)	1,307	(20)	3,152	4,084	(23)
Others	41	62	51	150	(59)	129	207	(38)
Sales Volume (BOED)	320,657	311,386	(3)	320,795	(3)	320,600	317,383	1
Sales Price (USD/BOE)	36.62	36.32	(1)	44.83	(19)	36.00	47.47	(24)
Total Expenses	1,028	953	(7)	2,710	(65)	2,896	5,245	(45)
Major Expenses:								
Operating Expenses	139	146	5	177	(18)	415	515	(19)
Exploration Expenses	15	20	33	78	(74)	61	129	(53)
DD&A	518	534	3	644	(17)	1,570	2,095	(25)
Impairment loss on assets	-	-	-	1,350	(100)	-	1,350	(100)
Income Tax Expense	55	67	22	220	(70)	152	377	(60)
(Gain)/Loss on FX	(7)	(14)	(100)	20	<(100)	(27)	73	<(100)
Net Income from Continuing Operations	74	156	>100	(1,253)	>100	385	(954)	>100
Profit (Loss) from Discontinued Operations	1	0.3	(70)	(31)	>100	3	(32)	>100
Net Income	75	156	>100	(1,284)	>100	388	(986)	>100
Recurring Net Income	154	75	(51)	264	(72)	345	705	(51)
Non-Recurring **	(79)	81	>100	(1,548)	>100	43	(1,691)	>100

Note: \* Restated / Represented


<sup>\*\*</sup> Includes Gain/(Loss) on FX, Deferred tax from Functional currency, Current Tax from FX Revaluation, Gain/(Loss) from Financial Instruments, and etc.


# PTTEP Sales Volume & Average Selling Price





#### Sales Volume






Note: \* Restated

<sup>\*\*</sup> Includes discontinued operations until end of August 2016

## **Operating Performance**







Note: \* Restated

The formulas for calculating ratios are provided in the supplementary section for your reference

<sup>\*\*</sup> Includes discontinued operations until end of August 2016

<sup>\*\*\*</sup> Exploration and Appraisal Wells

### Financial Performance: Income Statement

Maintain strong EBITDA margin reflecting efficiency in cost reduction



	Q2 16 *	Q3 16	Q3 15 *	9M 16	9M 15 *
Sales Revenue ** (MMUSD)	1,085	1,065	1,337	3,204	4,179
EBITDA *** (MMUSD)	778	770	919	2,337	3,025
Net Income (MMUSD)	75	156	(1,284)	388	(986)
Recurring Net Income (MMUSD)	154	75	264	345	705
Earning Per Share (USD)	0.01	0.04	(0.32)	0.09	(0.25)
Key Financial Ratios ***					
EBITDA Margin (%)	72	72	69	73	72
Return on Equity (%) (LTM)	(7)	5	(14)	5	(14)
Return on Capital Employed (%) (LTM)	(5)	4	(10)	4	(10)
Return on Equity (%) (LTM, Recurring Net Income)	5	3	7	3	7
Return on Capital Employed (%) (LTM, Recurring Net Income)	4	3	6	3	6

Note: \* Restated / Represented

The formulas for calculating ratios are provided in the supplementary section for your reference

<sup>\*\*</sup> Sales and revenue from pipeline transportation

<sup>\*\*\*</sup> Includes discontinued operations until end of August 2016

#### Financial Performance: Balance Sheet

Solid balance sheet with \$3.7Bn cash on hand for future growth



	Q4 15	Q1 16	Q2 16	Q3 16
Total Assets (MMUSD)	19,642	19,795	19,025	19,062
- Cash & cash equivalents * (MMUSD)	3,260	3,702	3,205	3,722
Total Liabilities (MMUSD)	8,314	8,509	7,704	7,643
- Interest bearing debt (MMUSD)	3,005	3,018	2,844	2,855
Equity (MMUSD)	11,328	11,286	11,321	11,419
Key Financial Ratios ***				
Total Debt to Equity (X)	0.27	0.27	0.25	0.25
Net Debt * to Equity (X)	(0.02)	(0.06)	(0.03)	(0.08)
Total Debt to Capital (X)	0.21	0.21	0.20	0.20
Total Debt to EBITDA (X)	0.78	0.85	0.86	0.91
Net Debt * to EBITDA (X)	(0.07)	(0.19)	(0.11)	(0.28)
EBITDA Interest Coverage (X)	24	24	24	23

Credit Ratings: BBB+ (S&P), Baa1 (Moody's), AAA (TRIS)

Weighted Average Cost of Debt \*\*: 4.37%

Average Loan Life \*\*: 8.40 years

Note: \* Cash & Cash Equivalents (Cash on hand) include Short-term Investments (Fixed deposit > 3 months)

Net Debt = Total Debt less Cash & Cash Equivalents and Short-term Investments

The formulas for calculating ratios are provided in the supplementary section for your reference

<sup>\*\*</sup> Excludes hybrid bonds

<sup>\*\*\*</sup> Includes discontinued operations until end of August 2016

# Cash Flows: January – September 2016

Robust cash position and positive operating cash flow



Unit: MMUSD

Operating	1,727				CAPEX & Inve	estment	(807)
Income before tax & non-cash adjustment	2,394				PEX (PP&E, Intangible	asset)	(813)
	(FO7)	+		■ Otl	ners		6
■ Tax payment	(537)						
Changes in assets/liabilities *	(94)						
EBITDA**** 2,337 MMUS\$							
2,007 11111000					Fin	ance	(458)
					■ Net interest paid **	* & Finance cost paid	(119)
	Free Cas	sh Flow			■ Bond buy back		(184)
	1100 040			_	■ Dividend paid		(310)
	92	0			Cash received from	m financial derivative	155
					contract		
	Cash In (Out)				Beginning Cash & Cash Equivalent***	Ending Bala	ance***
a. * Not of fouciers avaloging a vota official	462	2	+		3,260	3,72	2

Note: \* Net of foreign exchange rate effect

\*\* Net of interest received

7/9

<sup>\*\*\*</sup> Include Short-term investment (Fixed deposit > 3 months)

<sup>\*\*\*\*</sup> Includes discontinued operations until end of August 2016

## Key Takeaway: Q3 2016 Financial Results



#### **Summary of Statement of Profit and Loss:**

Unit: MMUSD

Statement of Income	Q2 16 *	Q3 16	% QoQ	Q3 15 *	% YoY	9M 16	9M 15 *	% YTD
Net Income	75	156	>100	(1,284)	>100	388	(986)	>100
Recurring Net Income	154	75	(51)	264	(72)	345	705	(51)
Non-Recurring **	(79)	81	>100	(1,548)	>100	43	(1,691)	>100

- ✓ Solid operational performance: On track to achieve 2016 sales volume target
- ✓ Efficient cost management : alleviating impact of low oil price and driving competitive advantage
- ✓ Strong EBITDA margin: leading to healthy operating cash flow and high levels of liquidity
- \$3.7Bn cash on hand + Strong balance sheet: well positioned for M&A and ready to weather through low oil prices

Remark: Cash on hand includes short-term investments

Note: \* Restated / Represented

<sup>\*\*</sup> Includes Gain/(Loss) on FX, Deferred tax from Functional currency, Current Tax from FX Revaluation, Gain/(Loss) from Financial Instruments, and etc.

# Thank you and Q&A





You can reach the Investor Relations team for more information and inquiry through the following channels:



http://www.pttep.com



IR@pttep.com



+66 2 537 4000

# Supplementary Index : Ratio & Formula



Ratio	Formula
Lifting Cost (\$/BOE)	(Operating Exp. – Transportation Cost – Stock Variation – Other expense not related to lifting) / Production Volume
Cash Cost (\$/BOE)	(Operating Exp. + Exploration Exp. + G&A + Royalties + Finance Cost) / Sales Volume
Unit Cost (\$/BOE)	(Operating Exp. + Exploration Exp. + G&A + Royalties + Finance Cost + DD&A) / Sales Volume
Reserves Replacement Ratio	5-Yr Additional Proved Reserves / 5-Yr Production Volume
Reserves Life Index (Year)	Proved Reserves / Production Volume
Success Ratio	Number of wells with petroleum discovery / Total number of exploration and appraisal wells
Sales Revenue	Sales + Revenue from pipeline transportation
EBITDA	(Sales + Revenue from pipeline transportation) - (Operating expenses + Exploration expenses + Administrative expenses + Petroleum royalties and remuneration + Management's remuneration)
EBITDA Margin	EBITDA / Sales Revenue
Return on Equity	Trailing-12-month net income / Average shareholders' equity between the beginning and the end of the 12-month period
Return on Capital Employed	(Trailing-12-month net income + Trailing-12-month Interest Expenses & Amortize Bond Issuing Cost) / (Average shareholders' equity and average total debt between the beginning and the end of the 12-month period)
Simple Effective Tax Rate	Income tax expenses / Income before income taxes
Total debt	Short-term loans from financial institution + Current portion of long-term debts + Bonds + Long-term loans from financial institution
Net debt	Total debt – Liquidity
Debt to Equity	Total debt / Shareholders' equity
Net Debt to Equity	Net debt / Shareholders' equity
Total Debt to Capital	Total debt / (Total debt + Shareholders' equity)
Total Debt to EBITDA	Total debt / Trailing-12-month EBITDA
Net Debt to EBITDA	Net debt / Trailing-12-month EBITDA
EBITDA Interest Coverage Ratio	Trailing-12-month EBITDA / Trailing-12-month Interest Expenses & Amortize Bond Issuing Cost